Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies

Journal of Experimental Medicine

Volumn 210, Issue 2, 2013, Pages 241-256

  Yang, Guang ^a   Holl, T Matt ^a   Liu, Yang ^a   Li, Yi ^a   Lu, Xiaozhi ^b   Nicely, Nathan I ^b   Kepler, Thomas B ^a,c   Alam Munir, S ^b   Liao, Hua Xin ^b   Cain, Derek W ^a   Spicer, Leonard ^c   VandeBerg, John L ^d   Haynes, Barton F ^a,b   Kelsoe, Garnett ^a,b  

^a Department of Immunology ^*  (United States)

^b Human Vaccine Institute   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; EPITOPE; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS 1 NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; KYNURENINASE; NEUTRALIZING ANTIBODY; SPLICING FACTOR 3B SUBUNIT 3; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; NONHUMAN; OPOSSUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; VIRUS ENVELOPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; AUTOANTIGENS; B-LYMPHOCYTES; CELL LINE; CONSERVED SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; HYDROLASES; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNE TOLERANCE; IMMUNIZATION; MICE; OPOSSUMS; PHYLOGENY; RNA-BINDING PROTEINS;

EID: 84874562109     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20121977     Document Type: Article

References (80)

1. Adams, E., A. Basten, and C.C. Goodnow. 1990. Intrinsic B-cell hyporesponsiveness accounts for self-tolerance in lysozyme/anti-lysozyme double-transgenic mice. Proc. Natl. Acad. Sci. USA. 87:5687-5691. http://dx.doi.org/10.1073/pnas.87.15.5687
2. Alam, S.M., M. McAdams, D. Boren, M. Rak, R.M. Scearce, F. Gao, Z.T. Camacho, D. Gewirth, G. Kelsoe, P. Chen, and B.F. Haynes. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
3. Alam, S.M., R.M. Scearce, R.J. Parks, K. Plonk, S.G. Plonk, L.L. Sutherland, M.K. Gorny, S. Zolla-Pazner, S. Vanleeuwen, M.A. Moody, et al. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82:115- 125. http://dx.doi.org/10.1128/JVI.00927-07
4. Alam, S.M., M. Morelli, S.M. Dennison, H.X. Liao, R. Zhang, S.M. Xia, S. Rits-Volloch, L. Sun, S.C. Harrison, B.F. Haynes, and B. Chen. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 106:20234-20239. http://dx.doi.org/10.1073/pnas.0908713106
5. Alam, S.M., H.X. Liao, S.M. Dennison, F. Jaeger, R. Parks, K. Anasti, A. Foulger, M. Donathan, J. Lucas, L. Verkoczy, et al. 2011. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J. Virol. 85:11725-11731. http://dx.doi.org/10.1128/JVI.05680-11
6. André, S., B. Seed, J. Eberle, W. Schraut, A. Bültmann, and J. Haas. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72: 1497-1503.
7. Balazs, A.B., J. Chen, C.M. Hong, D.S. Rao, L. Yang, and D. Baltimore. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 481:81-84. http://dx.doi.org/10.1038/nature10660
8. Bowes, T., E.R. Wagner, J. Boffey, D. Nicholl, L. Cochrane, M. Benboubetra, J. Conner, K. Furukawa, K. Furukawa, and H.J. Willison. 2002. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Infect. Immun. 70:5008-5018. http://dx.doi.org/10.1128/IAI.70.9.5008-5018.2002
9. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses. 10:359-369. http://dx.doi.org/10.1089/aid.1994.10.359
10. Burton, D.R., R.C. Desrosiers, R.W. Doms, W.C. Koff, P.D. Kwong, J.P. Moore, G.J. Nabel, J. Sodroski, I.A. Wilson, and R.T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236. http://dx.doi.org/10.1038/ni0304-233
11. Burton, D.R., P. Poignard, R.L. Stanfield, and I.A. Wilson. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 337:183-186. http://dx.doi.org/10.1126/science.1225416
12. Chen, C., Z. Nagy, E.L. Prak, and M. Weigert. 1995. Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Immunity. 3:747-755. http://dx.doi.org/10.1016/1074-7613(95)90064-0
13. Coëffier, E., J.M. Clément, V. Cussac, N. Khodaei-Boorane, M. Jehanno, M. Rojas, A. Dridi, M. Latour, R. El Habib, F. Barré-Sinoussi, et al. 2000. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine. 19:684-693. http://dx.doi.org/10.1016/S0264-410X(00)00267-X
14. Das, B.K., L. Xia, L. Palandjian, O. Gozani, Y. Chyung, and R. Reed. 1999. Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. Mol. Cell. Biol. 19:6796-6802.
15. Dennison, S.M., L.L. Sutherland, F.H. Jaeger, K.M. Anasti, R. Parks, S.M. Stewart, C. Bowman, S.M. Xia, R. Zhang, X. Shen, et al. 2011. Induction of antibodies in rhesus macaques that recognize a fusionintermediate conformation of HIV-1 gp41. PLoS ONE. 6:e27824. http://dx.doi.org/10.1371/journal.pone.0027824
16. Derby, N.R., Z. Kraft, E. Kan, E.T. Crooks, S.W. Barnett, I.K. Srivastava, J.M. Binley, and L. Stamatatos. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol. 80:8745-8762. http://dx.doi.org/10.1128/JVI.00956-06
17. Eckhart, L., W. Raffelsberger, B. Ferko, A. Klima, M. Purtscher, H. Katinger, and F. Rüker. 1996. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77:2001-2008. http://dx.doi.org/10.1099/0022-1317-77-9-2001
18. Erikson, J., M.Z. Radic, S.A. Camper, R.R. Hardy, C. Carmack, and M. Weigert. 1991. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature. 349:331-334. http://dx.doi.org/10.1038/349331a0
19. Gay, D., T. Saunders, S. Camper, and M. Weigert. 1993. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177:999-1008. http://dx.doi.org/10.1084/jem.177.4.999
20. Goodnow, C.C. 1992. Transgenic mice and analysis of B-cell tolerance. Annu. Rev. Immunol. 10:489-518. http://dx.doi.org/10.1146/annurev.iy.10.040192.002421
21. Guenaga, J., P. Dosenovic, G. Ofek, D. Baker, W.R. Schief, P.D. Kwong, G.B. Karlsson Hedestam, and R.T. Wyatt. 2011. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE. 6:e16074. http://dx.doi.org/10.1371/journal.pone.0016074
22. Hager-Braun, C., H. Katinger, and K.B. Tomer. 2006. The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen. J. Immunol. 176:7471-7481.
23. Han, S., B. Zheng, J. Dal Porto, and G. Kelsoe. 1995. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. J. Exp. Med. 182:1635-1644. http://dx.doi.org/10.1084/jem.182.6.1635
24. Hartley, S.B., J. Crosbie, R. Brink, A.B. Kantor, A. Basten, and C.C. Goodnow. 1991. Elimination from peripheral lymphoid tissues of selfreactive B lymphocytes recognizing membrane-bound antigens. Nature. 353:765-769. http://dx.doi.org/10.1038/353765a0
25. Hartley, S.B., M.P. Cooke, D.A. Fulcher, A.W. Harris, S. Cory, A. Basten, and C.C. Goodnow. 1993. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell. 72:325-335. http://dx.doi.org/10.1016/0092-8674(93)90111-3
26. Haynes, B.F., and D.C. Montefiori. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines. 5:579-595. http://dx.doi.org/10.1586/14760584.5.4.579
27. Haynes, B.F., J. Fleming, E.W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R.M. Scearce, K. Plonk, H.F. Staats, et al. 2005a. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 308:1906-1908. http://dx.doi.org/10.1126/science.1111781
28. Haynes, B.F., M.A. Moody, L. Verkoczy, G. Kelsoe, and S.M. Alam. 2005b. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies. 14:59-67.
29. Haynes, B.F., G. Kelsoe, S.C. Harrison, and T.B. Kepler. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30:423-433. http://dx.doi.org/10.1038/nbt.2197
30. Hessell, A.J., L. Hangartner, M. Hunter, C.E. Havenith, F.J. Beurskens, J.M. Bakker, C.M. Lanigan, G. Landucci, D.N. Forthal, P.W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 449:101-104. http://dx.doi.org/10.1038/nature06106
31. Hessell, A.J., E.G. Rakasz, D.M. Tehrani, M. Huber, K.L. Weisgrau, G. Landucci, D.N. Forthal, W.C. Koff, P. Poignard, D.I. Watkins, and D.R. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84:1302-1313. http://dx.doi.org/10.1128/JVI.01272-09
32. Julien, J.P., S. Bryson, J.L. Nieva, and E.F. Pai. 2008. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol. 384:377-392. http://dx.doi.org/10.1016/j.jmb.2008.09.024
33. Kain, R., M. Exner, R. Brandes, R. Ziebermayr, D. Cunningham, C.A. Alderson, A. Davidovits, I. Raab, R. Jahn, O. Ashour, et al. 2008. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 14:1088-1096. http://dx.doi.org/10.1038/nm.1874
34. Kuraoka, M., T.M. Holl, D. Liao, M. Womble, D.W. Cain, A.E. Reynolds, and G. Kelsoe. 2011. Activation-induced cytidine deaminase mediates central tolerance in B cells. Proc. Natl. Acad. Sci. USA. 108:11560-11565. http://dx.doi.org/10.1073/pnas.1102571108
35. Lang, J., M. Jackson, L. Teyton, A. Brunmark, K. Kane, and D. Nemazee. 1996. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. J. Exp. Med. 184:1685-1697. http://dx.doi.org/10.1084/jem.184.5.1685
36. Liao, H.X., X. Chen, S. Munshaw, R. Zhang, D.J. Marshall, N. Vandergrift, J.F. Whitesides, X. Lu, J.S. Yu, K.K. Hwang, et al. 2011. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 208:2237-2249. http://dx.doi.org/10.1084/jem.20110363
37. Lima, S., R. Khristoforov, C. Momany, and R.S. Phillips. 2007. Crystal structure of Homo sapiens kynureninase. Biochemistry. 46:2735-2744. http://dx.doi.org/10.1021/bi0616697
38. MacLennan, I.C. 1994. Germinal centers. Annu. Rev. Immunol. 12:117-139. http://dx.doi.org/10.1146/annurev.iy.12.040194.001001
39. Mallery, D.L., W.A. McEwan, S.R. Bidgood, G.J. Towers, C.M. Johnson, and L.C. James. 2010. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl. Acad. Sci. USA. 107:19985-19990. http://dx.doi.org/10.1073/pnas.1014074107
40. Mascola, J.R. 2003. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3:209-216. http://dx.doi.org/10.2174/1566524033479799
41. Mascola, J.R., M.G. Lewis, G. Stiegler, D. Harris, T.C. VanCott, D. Hayes, M.K. Louder, C.R. Brown, C.V. Sapan, S.S. Frankel, et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
42. Mascola, J.R., G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, and M.G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210. http://dx.doi.org/10.1038/72318
43. Matyas, G.R., Z. Beck, N. Karasavvas, and C.R. Alving. 2009. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta. 1788:660-665. http://dx.doi.org/10.1016/j.bbamem.2008.11.015
44. Meffre, E., A. Schaefer, H. Wardemann, P. Wilson, E. Davis, and M.C. Nussenzweig. 2004. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J. Exp. Med. 199:145-150. http://dx.doi.org/10.1084/jem.20031550
45. Mietzner, B., M. Tsuiji, J. Scheid, K. Velinzon, T. Tiller, K. Abraham, J.B. Gonzalez, V. Pascual, D. Stichweh, H. Wardemann, and M.C. Nussenzweig. 2008. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc. Natl. Acad. Sci. USA. 105:9727-9732. http://dx.doi.org/10.1073/pnas.0803644105
46. Moir, S., T.W. Chun, and A.S. Fauci. 2011. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6:223-248. http://dx.doi.org/10.1146/annurev-pathol-011110-130254
47. Montero, M., N.E. van Houten, X. Wang, and J.K. Scott. 2008. The membrane- proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72:54-84 (table of contents.). http://dx.doi.org/10.1128/MMBR.00020-07
48. Mouquet, H., J.F. Scheid, M.J. Zoller, M. Krogsgaard, R.G. Ott, S. Shukair, M.N. Artyomov, J. Pietzsch, M. Connors, F. Pereyra, et al. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 467:591-595. http://dx.doi.org/10.1038/nature09385
49. Mouquet, H., M. Warncke, J.F. Scheid, M.S. Seaman, and M.C. Nussenzweig. 2012. Enhanced HIV-1 neutralization by antibody heteroligation. Proc. Natl. Acad. Sci. USA. 109:875-880. http://dx.doi.org/10.1073/pnas.1120059109
50. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
51. Nelson, J.D., F.M. Brunel, R. Jensen, E.T. Crooks, R.M. Cardoso, M. Wang, A. Hessell, I.A. Wilson, J.M. Binley, P.E. Dawson, et al. 2007. An affinity-enhanced neutralizing antibody against the membraneproximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81:4033-4043. http://dx.doi.org/10.1128/JVI.02588-06
52. Nemazee, D.A., and K. Bürki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature. 337:562-566. http://dx.doi.org/10.1038/337562a0
53. Ofek, G., M. Tang, A. Sambor, H. Katinger, J.R. Mascola, R. Wyatt, and P.D. Kwong. 2004. Structure and mechanistic analysis of the antihuman immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724-10737. http://dx.doi.org/10.1128/JVI.78.19.10724-10737.2004
54. Ofek, G., F.J. Guenaga, W.R. Schief, J. Skinner, D. Baker, R. Wyatt, and P.D. Kwong. 2010a. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA. 107:17880-17887. http://dx.doi.org/10.1073/pnas.1004728107
55. Ofek, G., K. McKee, Y. Yang, Z.Y. Yang, J. Skinner, F.J. Guenaga, R. Wyatt, M.B. Zwick, G.J. Nabel, J.R. Mascola, and P.D. Kwong. 2010b. Relationship between antibody 2F5 neutralization of HIV- 1 and hydrophobicity of its heavy chain third complementaritydetermining region. J. Virol. 84:2955-2962. http://dx.doi.org/10.1128/JVI.02257-09
56. Pulendran, B., G. Kannourakis, S. Nouri, K.G. Smith, and G.J. Nossal. 1995. Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. Nature. 375:331-334. http://dx.doi.org/10.1038/375331a0
57. Saito, Y., O. Hayaishi, and S. Rothberg. 1957. Studies on oxygenases; enzymatic formation of 3-hydroxy-L-kynurenine from L-kynurenine. J. Biol. Chem. 229:921-934.
58. Scherer, E.M., M.B. Zwick, L. Teyton, and D.R. Burton. 2007. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS. 21:2131-2139. http://dx.doi.org/10.1097/QAD.0b013e3282a4a632
59. Scherer, E.M., D.P. Leaman, M.B. Zwick, A.J. McMichael, and D.R. Burton. 2010. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. USA. 107:1529-1534. http://dx.doi.org/10.1073/pnas.0909680107
60. Shen, X., R.J. Parks, D.C. Montefiori, J.L. Kirchherr, B.F. Keele, J.M. Decker, W.A. Blattner, F. Gao, K.J. Weinhold, C.B. Hicks, et al. 2009. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 83:3617-3625. http://dx.doi.org/10.1128/JVI.02631-08
61. Shokat, K.M., and C.C. Goodnow. 1995. Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature. 375:334-338. http://dx.doi.org/10.1038/375334a0
62. Smith, K., L. Garman, J. Wrammert, N.Y. Zheng, J.D. Capra, R. Ahmed, and P.C. Wilson. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4:372-384. http://dx.doi.org/10.1038/nprot.2009.3
63. Soda, K., and K. Tanizawa. 1979. Kynureninases: enzymological properties and regulation mechanism. Adv. Enzymol. Relat. Areas Mol. Biol. 49:1-40.
64. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 17:1757-1765. http://dx.doi.org/10.1089/08892220152741450
65. Sun, Z.Y., K.J. Oh, M. Kim, J. Yu, V. Brusic, L. Song, Z. Qiao, J.H. Wang, G. Wagner, and E.L. Reinherz. 2008. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity. 28:52-63. http://dx.doi.org/10.1016/j.immuni.2007.11.018
66. Thornburg, N.J., C.A. Ray, M.L. Collier, H.X. Liao, D.J. Pickup, and R.E. Johnston. 2007. Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. Virology. 362:441-452. http://dx.doi.org/10.1016/j.virol.2007.01.001
67. Tiegs, S.L., D.M. Russell, and D. Nemazee. 1993. Receptor editing in selfreactive bone marrow B cells. J. Exp. Med. 177:1009-1020. http://dx.doi.org/10.1084/jem.177.4.1009
68. Tiller, T., M. Tsuiji, S. Yurasov, K. Velinzon, M.C. Nussenzweig, and H. Wardemann. 2007. Autoreactivity in human IgG+ memory B cells. Immunity. 26:205-213. http://dx.doi.org/10.1016/j.immuni.2007.01.009
69. Tomaras, G.D., J.M. Binley, E.S. Gray, E.T. Crooks, K. Osawa, P.L. Moore, N. Tumba, T. Tong, X. Shen, N.L. Yates, et al. 2011. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85:11502-11519. http://dx.doi.org/10.1128/JVI.05363-11
70. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622. http://dx.doi.org/10.1038/nm1244
71. Tsuiji, M., S. Yurasov, K. Velinzon, S. Thomas, M.C. Nussenzweig, and H. Wardemann. 2006. A checkpoint for autoreactivity in human IgM+ memory B cell development. J. Exp. Med. 203:393-400. http://dx.doi.org/10.1084/jem.20052033
72. Vcelar, B., G. Stiegler, H.M. Wolf, W. Muntean, B. Leschnik, S. Mehandru, M. Markowitz, C. Armbruster, R. Kunert, M.M. Eibl, and H. Katinger. 2007. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS. 21:2161-2170. http://dx.doi.org/10.1097/QAD.0b013e328285da15
73. Verkoczy, L., M. Diaz, T.M. Holl, Y.B. Ouyang, H. Bouton-Verville, S.M. Alam, H.X. Liao, G. Kelsoe, and B.F. Haynes. 2010. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. USA. 107:181-186. http://dx.doi.org/10.1073/pnas.0912914107
74. Verkoczy, L., Y. Chen, H. Bouton-Verville, J. Zhang, M. Diaz, J. Hutchinson, Y.B. Ouyang, S.M. Alam, T.M. Holl, K.K. Hwang, et al. 2011. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. J. Immunol. 187:3785-3797. http://dx.doi.org/10.4049/jimmunol.1101633
75. Wardemann, H., S. Yurasov, A. Schaefer, J.W. Young, E. Meffre, and M.C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science. 301:1374-1377. http://dx.doi.org/10.1126/science.1086907
76. Wardemann, H., J. Hammersen, and M.C. Nussenzweig. 2004. Human autoantibody silencing by immunoglobulin light chains. J. Exp. Med. 200:191-199. http://dx.doi.org/10.1084/jem.20040818
77. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1884-1888. http://dx.doi.org/10.1126/science.280.5371.1884
78. Yu, R.K., T. Ariga, S. Usuki, and K. Kaida. 2011. Pathological roles of ganglioside mimicry in Guillain-Barré syndrome and related neuropathies. Adv. Exp. Med. Biol. 705:349-365. http://dx.doi.org/10.1007/978-1-4419-7877-6_17
79. Yuste, E., H.B. Sanford, J. Carmody, J. Bixby, S. Little, M.B. Zwick, T. Greenough, D.R. Burton, D.D. Richman, R.C. Desrosiers, and W.E. Johnson. 2006. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J. Virol. 80:3030-3041. http://dx.doi.org/10.1128/JVI.80.6.3030-3041.2006
80. Zwick, M.B., A.F. Labrijn, M. Wang, C. Spenlehauer, E.O. Saphire, J.M. Binley, J.P. Moore, G. Stiegler, H. Katinger, D.R. Burton, and P.W. Parren. 2001. Broadly neutralizing antibodies targeted to the membraneproximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905. http://dx.doi.org/10.1128/JVI.75.22.10892-10905.2001